Trial Profile

A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, and Efficacy of RZ-001 in Combination with Valganciclovir in Subjects with Glioblastoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2026 According to RZNOMICS Inc.'s media release, company expects to further establish the full clinical value of the therapy through additional patient enrollment and extended follow-up observations.
15 Jun 2026 Interim results (n=10) presented in a RZNOMICS Inc. media release
15 Jun 2026 According to RZNOMICS Inc. media release, company announced phase 1/2a interim clinical results, which were presented on June 13th at the Asian Society for Neuro-Oncology Annual Meeting (ASNO 2026) held in Kanazawa, Japan, by Dr. Chae-Yong Kim

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com